China vs. Cancer

Within the last two years, the regulatory environment has evolved dramatically in China, allowing clinical trials to get off the ground faster and providing greater opportunity for drug development in the region. Syneos Health® experts Patrick Nealon, Executive Vice President and Head of the Oncology Business Unit, and Nick Kenny, Chief Scientific Officer, discuss the extraordinary pace of investment and innovation in cancer drug development in China, the risks and challenges that arise...